Inhibrx Biosciences, Inc. short interest in 2025
In 2025, Inhibrx Biosciences, Inc.'s disclosed short interest ran from 8.89% of shares outstanding on 15 Jan 2025 to 11.78% on 31 Dec 2025, a change of +2.89 percentage points. The year's high was 11.78% on 31 Dec 2025 and its low 3.62% on 30 Sep 2025, averaging 6.45% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.48 days on 14 Feb 2025. Full history: Inhibrx Biosciences, Inc..
Cite this page
2025 in figures
- Start of year
- 8.89% (15 Jan 2025)
- End of year
- 11.78% (31 Dec 2025)
- Change
- +2.89 pp
- High
- 11.78% (31 Dec 2025)
- Low
- 3.62% (30 Sep 2025)
- Average
- 6.45%
- Highest days to cover
- 17.48 (14 Feb 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 8.89% | 16.11 | |
| 31 Jan 2025 | 8.43% | 10.78 | |
| 14 Feb 2025 | 8.83% | 17.48 | |
| 28 Feb 2025 | 8.19% | 15.84 | |
| 14 Mar 2025 | 6.60% | 7.95 | |
| 31 Mar 2025 | 6.45% | 11.58 | 10-K filed, results (8-K) |
| 15 Apr 2025 | 5.23% | 4.12 | |
| 30 Apr 2025 | 5.04% | 8.35 | |
| 15 May 2025 | 5.22% | 7.42 | 10-Q filed, results (8-K) |
| 30 May 2025 | 4.88% | 7.19 | |
| 13 Jun 2025 | 5.41% | 11.68 | |
| 30 Jun 2025 | 4.91% | 7.44 | |
| 15 Jul 2025 | 6.21% | 5.50 | |
| 31 Jul 2025 | 4.68% | 5.66 | |
| 15 Aug 2025 | 5.16% | 8.80 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 5.47% | 6.33 | |
| 15 Sep 2025 | 4.98% | 7.53 | |
| 30 Sep 2025 | 3.62% | 3.52 | |
| 15 Oct 2025 | 3.68% | 3.30 | |
| 31 Oct 2025 | 7.08% | 1.00 | |
| 14 Nov 2025 | 7.81% | 3.28 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 9.08% | 5.08 | |
| 15 Dec 2025 | 7.22% | 5.33 | |
| 31 Dec 2025 | 11.78% | 6.17 |
See also: Inhibrx Biosciences, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.